Dr. Tyler Martin is the Chairman and CEO of Adjuvance Technologies, a vaccine adjuvant company, with headquarters in Lincoln, NE, based on intellectual property from Memorial Sloan Kettering Cancer Center in New York, NY. Prior to Adjuvance, he held senior leadership positions in a number of biotech companies including Chiron, Sangamo, and Dynavax. He has led teams that filed more than 100 Investigational New Drug (IND) Applications including two adjuvanted vaccines approved by major regulatory authorities, Fluad and Heplisav-B. In addition to other targets, Adjuvance is currently evaluating the utility of their lead adjuvant with COVID-19 vaccines.
Speaking In
[Available On-Demand]
Adjuvance Technologies is a privately held biopharmaceutical company dedicated to empowering health…